James Nicole E, Chichester Clinton, Ribeiro Jennifer R
Division of Gynecologic Oncology, Program in Women's Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI, United States.
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, United States.
Front Oncol. 2018 Apr 24;8:124. doi: 10.3389/fonc.2018.00124. eCollection 2018.
Human epididymis protein 4 (HE4) is an important clinical biomarker used for the detection of epithelial ovarian cancer (EOC). While much is known about the predictive power of HE4 clinically, less has been reported regarding its molecular role in the progression of EOC. A deeper understanding of HE4's mechanistic functions may help contribute to the development of novel targeted therapies. Thus far, it has been difficult to recommend HE4 as a therapeutic target owing to the fact that its role in the progression of EOC has not been extensively evaluated. This review summarizes what is collectively known about HE4 signaling and how it functions to promote tumorigenesis, chemoresistance, and metastasis in EOC, with the goal of providing valuable insights that will have the potential to aide in the development of new HE4-targeted therapies.
人附睾蛋白4(HE4)是用于检测上皮性卵巢癌(EOC)的一种重要临床生物标志物。虽然临床上对HE4的预测能力已有很多了解,但关于其在EOC进展中的分子作用报道较少。更深入地了解HE4的机制功能可能有助于新型靶向治疗的开发。迄今为止,由于其在EOC进展中的作用尚未得到广泛评估,因此很难将HE4推荐为治疗靶点。本综述总结了目前关于HE4信号传导的共识,以及它如何促进EOC的肿瘤发生、化疗耐药和转移,目的是提供有价值的见解,有可能有助于开发新的HE4靶向治疗方法。